Team Leader
Anne Murati
Hospital Researcher-Practitioner
Charlotte Savay
Engineer
Chiara Taroni
Post-Doctoral Fellow
Delphine Potier
Researcher
Dominique Payet-Bornet
Researcher
Geoffroy Venton
Lecturer-Researcher-Hospital practitioner
Julie Quessada
Engineer
Lia Nguyen
Engineer
Loreen Haboub
Post-Doctoral Fellow
Maeva Rodies
Doctoral student
Marie Loosveld
Hospital Researcher-Practitioner
Mathilde Poplineau
Researcher
Rahma AIT MAHFOUD
The Laboratory for Integrative Molecular Biology in Hematopoiesis and Leukemia deciphers the molecular mechanisms involved in the aging of hematopoietic stem cells, the initiation and development of leukemia and resistance to treatment.
Our main objective is to discover the molecular networks involved in regulating the fate of normal or pathological hematopoietic cells, which may represent vulnerabilities to be targeted.
Using mouse and cell models as well as patient samples, we integrate data from biochemical, epigenomic and omic approaches at the single-cell level to identify, characterize and manipulate key oncogenic pathways.
We work mainly on :
Acute myeloid leukemia and the accutisation of myeloproliferative disorders (PI: E. Duprez).
- Acute T-cell lymphocytic leukemia (PI: D. Payet).
The projects
The hematopoietic system deteriorates with age, and numerous changes have been observed in humans and mice, including a reduction in the production of red blood cells and lymphocytes, and a relative increase in the production of myeloid cells.
The result is a reduction in the number of adaptive immune cells, favoring immune senescence and the development of myeloid disorders.
With the aim of understanding the impact of aging on the hematopoietic system, we are developing projects using mouse models and patient samples to :
- Resolving hematopoietic stem cell heterogeneity and its evolution during aging.
- Study the factors influencing this heterogeneity and their contribution to myeloid diseases.
Acute myeloid leukemia (AML) is a serious hematological disease that occurs more frequently in the elderly. AML is highly heterogeneous at the molecular and cellular levels, and this heterogeneity contributes significantly to resistance to treatment.
In order to study the heterogeneity of AML and its evolution after treatment, we are developing transcriptomic and epigenomic analyses (in bulk and at the single-cell level) coupled with biochemical and PDX models.
We focus on epigenetically and/or genetically defined subgroups of AML to:
- Study EZH2 activities (canonical and non-canonical) in response to therapy in different AML subgroups.
- Characterize NPM-mut AML heterogeneity based on the H3K27me3HIST1high epigenetic biomarker.
T-acute lymphoblastic leukemia (T-ALL) results from the transformation of thymic progenitors blocked in their differentiation process. It is an aggressive hematological malignancy diagnosed in children and adults.
The prognosis of patients with T-ALL remains poor, particularly in cases of relapse/resistance. Our research aims to better understand the mechanisms of leukemogenesis and treatment resistance.
To achieve our goals we use "omics" approaches (scRNA-seq, exome-seq, ChIP-seq) to analyze :
- mouse models mimicking human T-ALL, in which we study the oncogenic pathways underlying thymocyte neoplastic transformation.
- human T-ALL samples to study intratumoral heterogeneity and characterize the subclones responsible for relapse
Team news
featured publications
12/2022
Poplineau M, Platet N, Mazuel A, Hérault L, N'Guyen L, Koide S, Nakajima-Takagi Y, Kuribayashi W, Carbuccia N, Haboub L, Vernerey J, Oshima M, Birnbaum D, Iwama A, Duprez E.
03/2022
Garciaz S, Guirguis AA, Müller S, Brown FC, Chan YC, Motazedian A, Rowe CL, Kuzich JA, Chan KL, Tran K, Smith L, MacPherson L, Liddicoat B, Lam EYN, Cañeque T, Burr ML, Litalien V, Pomilio G, Poplineau M, Duprez E, Dawson SJ, Ramm G, Cox AG, Brown KK, Huang DCS, Wei AH, McArthur K, Rodriguez R, Dawson MA.
02/2021
Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D.
05/2019
Poplineau M, Vernerey J, Platet N, N'guyen L, Hérault L, Esposito M, Saurin AJ, Guilouf C, Iwama A, Duprez E.
04/2018
Koubi M, Poplineau M, Vernerey J, N'Guyen L, Tiberi G, Garciaz S, El-Kaoutari A, Maqbool MA, Andrau JC, Guillouf C, Saurin AJ, Duprez E.
04/2016
Vincent-Fabert C, Platet N, Vandevelde A, Poplineau M, Koubi M, Finetti P, Tiberi G, Imbert AM, Bertucci F, Duprez E.
Labels, Funding and Partners
Like others, they were part of the team. Thank you to all those who have contributed to CRCM's excellence and impact.
